To Demonstrate the Relative Bioavailability of Metformin HCL 500 mg Extended Release (XR) Tablets Under Fasting Conditions

This study has been completed.
Sponsor:
Information provided by:
Sandoz
ClinicalTrials.gov Identifier:
NCT00882882
First received: April 16, 2009
Last updated: NA
Last verified: April 2009
History: No changes posted
  Purpose

To demonstrate the relative bioavailability of Metformin HCl 500 mg XR tablets under fasting conditions.


Condition Intervention Phase
Type II Diabetes
Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-equivalence Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Relative Bioavailability Study of Metformin HCL 500 mg XR Tablets Under Fasting Conditions

Resource links provided by NLM:


Further study details as provided by Sandoz:

Primary Outcome Measures:
  • Bioequivalence based on AUC and Cmax [ Time Frame: 23 days ] [ Designated as safety issue: No ]

Enrollment: 16
Study Start Date: June 2001
Study Completion Date: June 2001
Primary Completion Date: June 2001 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Experimental: 2
Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Drug: Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC
Active Comparator: 3
GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb
Active Comparator: 4
GLUCOPHAGE XR 500 mg Extended-Release Tablets Bristol-Myers Squibb
Drug: GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb

  Eligibility

Ages Eligible for Study:   19 Years to 49 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

  • Positive test results for HIV or hepatitis B or C.
  • Treatment for drug or alcohol dependence.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00882882

Sponsors and Collaborators
Sandoz Inc.
Investigators
Principal Investigator: So Ran Hong, M.D. Novum Independent Institutional Review Board
  More Information

No publications provided

Responsible Party: Eric Mittleberg, Ph.D, VP of Product Development, Sandoz Inc.
ClinicalTrials.gov Identifier: NCT00882882     History of Changes
Other Study ID Numbers: B013701
Study First Received: April 16, 2009
Last Updated: April 16, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Metformin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on October 01, 2014